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 6 
Abstract 
Background: Multiple Sclerosis (MS) is a chronic autoimmune disease that 
attacks the CNS. The immune attack on the CNS cause the damage of a 
substance, called myelin, which surrounds and protects the nerve fibres. 
MS is one of the most common causes of neurological disability in young 
adults. It is well established that axonal injury is a feature of multiple 
sclerosis (Charcot JM, 1880), that the extent of axonal injury is correlated 
with the degree of inflammation  (Trapp BD, 1998) at least in relapsing 
multiple sclerosis, and that a close association between inflammation and 
neurodegeneration might exist in all disease stages of multiple sclerosis 
(Kutzelnigg A, 2005;  Frischer J, 2009). However, the interdependence 
between focal inflammation, diffuse inflammation and 
neurodegeneration, and their relative contribution to clinical deficits 
remain ambiguous. Nevertheless, this point is central for understanding 
the mechanism of tissue injury in multiple sclerosis, which may have an 
effect on treatment. It has therefore been suggested that disability 
accrual at later MS stages is primarily driven by neurodegeneration and is 
largely independent of inflammation. These observations have led to a 
two-stage hypothesis, with the first stage representing a therapeutic 
window for modifying disease trajectory, which then becomes uniform in 
the second stage of disease (Leray E, 2010). This concept was also 
confirmed in others studies (Scalfari A, 2010; Stys PK, 2012). 
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Objective: to explore whether disability accrual in moderately and 
advanced MS is ascribable to the concept of multiple sclerosis as a two-
stage disease as proposed by Leray et al. (Leray E, 2010). 
Methods: The research was conducted using patients identified through 
the MS Centre of Montichiari (Brescia, Italy) which is a territory-based 
centre created in 1980 mainly for patients of Brescia and province.  
Patients were identified through the territory-based MS Centre of 
Montichiari (Brescia, Italy) which is a centre created The disability was 
graded using the Kurtzke Expanded Disability Status Scale (EDSS) and was 
evaluated through two different neurological disability epochs.  
In particular, a total of 227 (153 male and 74 female) out of 1442 MS 
relapsing-remitting patents diagnosed between 1980 and 2016 fulfilled 
the inclusion criteria for each epoch (pre- and post-EDSS 3). After defining 
disability milestone and selecting patients (see section 3.2), the EDSS 
disability trajectory slopes were studied. The outcome of interest were 
the disability EDSS trajectory slopes in the spam of time prior to and 
following the EDSS 3 status, that were calculated with a Mixed-Effect 
Model (MEM) over the pre- or the post- EDSS 3 scores (including the EDSS 
3 score in both). The disease progression slope and variability were 
respectively examined by the F Variance test through the individual EDSS 
slopes for the pre- and post-EDSS 3 periods. 
In order to investigate different longitudinal disability trajectories during 
pre- and post-EDSS 3 epoch, a Latent Class Mixed-effect Model (LCMM) 
was performed using the fitted EDSS values of the MEM as the dependent 
variable and the disease duration from MS diagnosis was entered as 
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covariate in the model. A linear disease duration term was used to specify 
for the random-effects in the latent process mixed model, i.e., the 
individual variation around the mean trajectory (of the individual's latent 
class). Models with one, two, three, etc., latent trajectory classes were fit 
and to select the best model in term of the number of classes detected, 
the parsimony seeks minimum values for information criteria (Akaike 
Information Criterion and, Bayesian Information Criterion) was adopted. 
Association among classification pre- and post-EDSS 3 epoch was 
performed using chi-square or Fisher's Exact Test. 
The disability trajectories over the disease course were studied, using 
again, the LCMM including disease duration as covariates with the EDSS 
disability score as the outcome measure. The linear disease duration were 
used to specify for the random-effects in the LCMM. After choosing the 
best model as describe above, univariate analysis was performed using 
logistic regression, to screen possible determinants of class membership 
among clinical and demographic characteristics, such as gender, 
familiarity, group of diagnosis, age at diagnosis, therapy delay, median 
among EDSS visits, age at on-set and EDSS at diagnosis. Those covariates 
with a p-value <0.05 were then selected for the multivariate analysis, 
where the logistic regression model was again used. Differences, with a 
p-value less than 0.05, were selected as significant. 
Results: To find a model that provides the best fit to the data for the pre- 
and post EDSS 3 epoch, five latent class models were performed 
increasing the number of classes from 1 until 5.  
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As regard the per-EDSS 3 epoch, the lowest Akaike Information Criterion 
(AIC) BIC and AIC were obtained for model with two latent trajectory 
classes (BIC= -23847.87; AIC= -23912.94). When patients were assigned 
to the two classes, based on maximum posterior probabilities, there were 
197 and 30 patients assigned to class 1 and 2, respectively. The mean of 
posterior probabilities in each class was 94% and 80%, for class 1 and 2, 
respectively. As regard distribution of the clinical and demographic 
characteristics in the two classes, similar gender, familiarity distribution, 
age at diagnosis and at onset means in two classes were observed, instead 
the EDSS at diagnosis mean in moderate disability class was greater than 
that in high disability class (1.83 versus 0.63).  
Considering post-EDSS 3 epoch, The lowest BIC and AIC were obtained for 
model with two latent trajectory classes (BIC= -32285.67; AIC= 32337.04). 
When patients were assigned to the two classes, based on maximum 
posterior probabilities, there were 159 and 68 patients assigned to class 
1 and 2 (mean of posterior probabilities in each class: 92% and 88%, 
respectively). As regard distribution of the clinical and demographic 
characteristics in the two classes, similar gender, familiarity distribution, 
EDSS at diagnosis mean, age at diagnosis and at onset means in two 
classes were observed. 
The disability trajectory slope mean was 0.08 (SD= 0.04) for pre-EDSS 3 
epoch while, a mean of 0.11 (SD=0.23) disability trajectory slope was 
estimated for the post-EDSS 3 epoch. The graphical evaluation showed 
that the disability trajectory slopes were differently and highly variable, as 
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significant evidenced by the F test to compare variances (F test for 
variance ratio=0.02; p-value<0.0001). 
The chi-square test, performed to assay whether observations on two 
variables were independent of each other, showed no significant 
association between the pre-EDSS 3 classes and the post-EDSS 3 classes 
(p-value = 0.6647). 
The disability trajectories over the disease course was studied on a total 
of 881 (602 female; 68.33%) disability EDSS score trajectories over the 
disease course of patents diagnosed between 1980 and 2016.  
Five Latent Class Mixed-effect Model (LCMM) increasing the number of 
classes from 1 until 5 were performed and the lowest Akaike Information 
Criterion (AIC) and, Bayesian Information Criterion (BIC) was obtained for 
model with three latent trajectory classes (AIC= 34984.11; BIC = 
35098.86). The gravical evaluation of the plot of the disability EDSS 
trajectory scores highlighted that two of 3 latent trajectory had very 
similar graphic trend, so it was decided to aggregate this two similar 
trajectory in one that it was defined as moderate disability trajectory.  
As regard distribution of the clinical and demographic characteristics in 
the two classes, the age at onset and at diagnosis means were greater in 
high disability class compared with those in moderate disability class, as 
significant evidenced by the univariate analysis (p-values: 0.0035 and 
0.0023, respectively). The multivariate analysis (Table 11) highlighted the 
significant effect of age at diagnosis on high disability class membership 
(p-values=0.0023). In particular, a one-unit increase in age at diagnosis 
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was associated with an increased chances 5% (OR=1.05) of having high 
disability class membership. 
Conclusion: The graphical and analytic evaluation among disability 
trajectory slopes in pre- and post-EDSS 3 epoch showed that they were 
differently and highly variable (see section 4.1). The Latent Class Growth 
Analysis identified two main disability trajectories in both pre- and post-
EDSS 3 epoch. No significant association, between the main disability 
trajectories, was observed using chi-square test (p-value = 0.6647). In 
contrast to the study of Leray et al. (Leray E, 2010), we have shown that 
disability trajectories in advanced MS are highly variable as recently 
showed by Lizak (Lizak N, 2017). Moreover, our results concur that the 
disability trajectories in advanced disease (post-EDSS 3) is independent of 
previous disability trajectories (pre-EDSS 3). 
Regarding disability trajectories over the disease course, the lowest BIC 
and AIC was obtained for model with three latent trajectory classes with 
a mean of posterior probabilities in each class of 55% 61% and 77%, 
respectively. Two trajectories out of 3 had very similar graphic trend, so it 
was decided to aggregate this two similar trajectory in one that it was 
defined as moderate disability trajectory. The next univariate and then 
multivariate analysis, performed to screen possible determinants of class 
membership among clinical and demographic characteristics, highlighted 
the significant effect of age at diagnosis on high disability class 
membership (p-values=0.0023). In particular, a one-unit increase in age 
at diagnosis was associated with an increased chances 5% (OR=1.05) of 
having high disability class membership.  
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1 Introduction 
Multiple sclerosis (MS) is a common, progressive neurodegenerative 
disease that typically strikes young adults in the prime of their life causing 
irreversible physical and mental disability. MS represents an immense 
long term burden for society. 
The disease devastates the lives of people with MS and their families, and 
places an immense long-term burden on society and healthcare system. 
The MS affects many young adults worldwide. Globally, the estimated 
number of people with MS has increased from 2.1 million in 2008 to 2.3 
million in 2016. The disease appears to be on the increase, but better 
reporting and diagnosis may have contributed to this change. 
The MS is found worldwide but becomes more common with increasing 
distance from the equator and is therefore most prevalent in North 
America, Europe, Australia and other high-income countries. Globally, the 
median estimated prevalence of MS is 30 people per 100000. Countries 
with the highest estimated prevalence included Hungary (176), Slovenia 
(150), Germany (149), USA (135), Canada (133), Czech Republic (130), 
Norway (125), Denmark (122), Poland (120) and Cyprus (110). 
The onset of MS typically occurs between the ages of 20 and 40 years, 
when individuals are most active and productive in many aspects of their 
lives and frequently leads to the loss of gainful employment and cognitive 
impairment is a large contributor to this high rate of unemployment. Since 
the MS strikes young adults with the potential for many decades of 
employment and family life, it is the leading cause of non-traumatic 
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disability among the young and middle-aged in many developed 
countries: across all age groups in the US, MS is the third most common 
cause of paralysis and of wheelchair use.  
Around two thirds of people with MS are women, a large number of 
whom are of childbearing age. 
Symptoms are distressing and exhausting. The most common types of 
initial clinical symptoms are sensory (40%), motor (39%), visual (30%) and 
fatigue related (30%). The range of symptoms experienced depends on 
the locations of the lesions in the central nervous system (CNS). 
The MS is progressive and irreversible. The damage occurs to myelin in 
the brain and spinal cord. In particular, the immune system mistakenly 
attacks myelin, disrupting the electrical signals that travel along nerves.  
In a healthy person, electrical signals controlling thought processes, 
movement and bodily functions travel efficiently along the nerve cells 
within the CNS, composed by brain, spinal cord and optic nerve. 
In MS, the body’s immune system wrongly attacks the insulating sheath 
(made of myelin) that surrounds nerve cells in CNS. The cause of this 
immune attack is unclear and seems to involve complex interactions 
between genetics and environmental risk factors. The myelin sheaths 
become inflamed in small patches (called lesions), which distort or 
interrupt the electrical signals that travel along nerve fibres. 
The immune system does its best to repair the myelin, but eventually the 
repair process is overwhelmed, the sheath is destroyed ad damage to 
nerve fibres occurs. 
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This cycle of immune attacks and repair can proceed undetected until a 
lesion occurs in an area of the brain responsible for complex functions, 
which manifests clinically as an attack of symptoms, or enough damage 
accumulates for clinical symptoms of progressive MS become apparent. 
1.1 Multiple sclerosis 
The MS is a chronic autoimmune disease that attacks the CNS. The 
immune attack on the CNS cause the damage of a substance, called 
myelin, that surrounds and protects the nerve fibres. In fact when any 
part of the myelin sheath or of nerve fibres is damaged or completely 
destroyed, nerve impulses traveling to and from the brain and the spinal 
cord are distorted or interrupted and a large variety of symptoms can 
occur. 
The process of damage of myelin, called demyelination, forms scar tissue 
(sclerosis), which give the disease its name. 
The demyelination cause a break-down of the blood-brain barrier (BBB) 
with consequent problems for brain cells and spinal cord to communicate 
with each other.  
Demyelination includes cortex and deep grey matter nuclei, as well as 
diffuse injury of normal-appearing white matter. The mechanisms 
responsible for the formation of focal lesions in different patients and in 
different stages of the disease as well as those involved in the induction 
of diffuse brain damage are complex and heterogeneous. 
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Damages all occur on a background of inflammatory reaction, composed 
of lymphocytes and activated macrophages or microglia, and show 
demyelination, in which axons are at least partly preserved. 
Inflammation is dominated by T cells and activated macrophages or 
microglia. In active lesions this inflammatory process is accompanied by a 
profound disturbance of the BBB, the local expression of pro 
inflammatory cytokines and chemokines as well as of their cognate 
receptors. In MS, however, the composition of inflammatory infiltrates in 
the lesions is different. In some cases of acute MS CD8+ T cells, which 
express grazyme B as a marker of cytotoxic activation, can be seen in close 
proximity or attachment to oligodendrocytes. Complete demyelination is 
accompanied by a variability degree of acute axonal injury and axonal loss 
which in part is counteracted by remyelination. When nerve fibres are 
damaged, the brain has some ability to re-route signals via undamaged 
fibres or compensate for the damage. This built-in ‘reserve’ can act as a 
buffer against cognitive decline at various stages of the disease, but the 
brain’s ability to ‘buffer’ against damage is finite. 
In general, the axons and cell bodies remain intact, despite the absence 
of myelin. Wallerian degeneration (i.e., axon destruction) may occur in 
MS, although typically it is described in chronic lesions. Consequently, the 
pathology in MS may not result in complete cessation of neural 
transmission, since axons and cell bodies are intact.  
Most studies on pathology and pathogenesis have so far concentrated on 
focal demyelinated lesions in the white matter mainly at the chronic 
disease stage. This plaque-centred view has recently been challenged by 
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magnetic resonance imaging (MRI) studies, which revealed a much more 
widespread and global damage of the brain and spinal cord, in particular 
in patients at late stages of the disease. Consequently, MS plaques do not 
localize to discrete systematized fibre tracts but they spread in a 
centrifugal manner. 
The most frequent symptoms are fatigue, numbness of face and body or 
extremities (arms and legs), vision problems, loss of balance and 
coordination with associated walking problems and others. Since these 
symptoms are very general and vary depending on where the cerebral 
damage has occurred, frequently it takes many years before MS is 
diagnosed and once it happens it is however very difficult to predict the 
progression of disease for each patient. 
The rarity of MS among Samis, Turkmen, Uzbeks, Kazakhs, Kyrgyzis, native 
Siberians, North and South Amerindians, Chinese, Japanese, African 
blacks and New Zealand Maoris, as well as the high risk among Sardinians, 
Parsis and Palestinians, clearly indicate that the different susceptibilities 
of distinct racial and ethnic groups are an important determinant of the 
uneven geographic distribution of the disease. 
Prevalence data imply that racial and ethnic differences are important in 
influencing the worldwide distribution of MS and that its geography must 
be interpreted in terms of the probable discontinuous distribution of 
genetic susceptibility alleles, which can however be modifies by 
environment. Because the environmental and genetic determinants of 
geographic gradients are by no means mutually exclusive, the race versus 
place controversy is, to some extent, a useless and sterile debate. 
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In Italy, during the last 30 years, the frequency of MS in the Italian 
peninsula and its two major islands, Sicily and Sardinia, has been studies 
in detail and by means of repeated assessments. The island of Sardinia 
represents a striking exception to the even distribution of MS in Italy. The 
most recent survey on large populations confirms the results of previous 
studies on small populations, indicating that this Italian island has the 
highest frequency of MS in Mediterranean Europe and one of the highest 
in the world. The prevalence of MS was 152 per 100 000 in the province 
of Nuoro in 1994 and 144 in the province of Sassari in 1997. Because of 
their peculiar genetic structure, Sardinians are probably more susceptible 
to the disease as compared to other Italians. The genetic distance of 
Sardinians from most present-day Europeans is second only to Samis and 
exceeds that of Basques; it is reflected by an unusually high frequency of 
some blood groups, HLA phenotypes and thalassemia variants that are 
rare elsewhere. These characteristics reflect several millennia of genetic 
drift in a small and isolated population.  
Environmental factors, anyway, are important. Among the considered 
environmental factors smoking was found as one of the important MS risk 
factors. Alcohol, coffee and smoking are connected with high EDSS score. 
Vitamin D insufficiency (linked with low UV exposition) activated the 
development of MS. Researchers provided a linear inverse relationship 
between the risk of MS and the level of education. They found increased 
risk of MS in women with migraine and probably in people using mobile 
phones at least for 13 years. 
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In Denmark besides genetic factors of MS manifestation, a few 
environmental contributions were investigated. The most important of 
these were the first infection with Epstein-Barr virus (threefold enhanced 
risk of MS) and the child’s lost (a 50% increased risk of developing MS in 
solitary parents). There were no associations between MS and childhood 
infections at specific ages, head injuries or exposure to organic solvents. 
It was possible to estimate the risk of cancer in MS patients. It was 
reduced by 16% in males and the same as in the background population 
in females (except breast cancer). The risk of developing MS was 
increased threefold in patients with diabetes mellitus type I. 
As currently only relapsing forms of MS are treatable. An increasing 
number of disease-modifying therapies (DMTs) that aim to alter the 
disease course have been approved for treating CIS and relapsing forms 
of MS. However none has been shown to be effective in treating PPMS or 
SPMS in its non-relapsing stage. 
It is important to diagnose as early as possible so that DMT can be initiated 
to prevent or delay the onset of further relapses or irreversible disability. 
Researchers suggest that neuropsychological tests could serve as early 
diagnostic tools to detect subtle disease progression that may require 
initiation of DMT. 
In recent years, an immunosuppressive regimen followed by the 
autologous hematopoietic stem cell transplantation (AHSCT) has been a 
new option for these patients and for other patients affected by several 
autoimmune disorders as well. It essentially consists in the replacement 
of defective bone marrow with a healthy and efficacious one. The target 
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of this treatment is the eradication of auto reactive cells, followed by the 
infusion of hematopoietic stem cells from previously stored bone marrow 
or blood cells from the patient (autologous), that either do not contain 
the autoimmune generating components or that have been purged of 
them. Stem cells (usually collected from the patient’s peripheral blood 
prior to conditioning) are reinfused after the conditioning regimen has 
been completed. 
Recently, on June 2016, despite the aggregation observed in some 
families, pathogenic mutations have remained elusive, Canadian 
scientists could describe the identification of NR1H3 p.Arg415Gln in seven 
progressive MS patients from two multi-incident families. The 
p.Arg415Gln position is highly conserved in orthologs and paralogs, and 
disrupts NR1H3 heterodimerization and transcriptional activation of 
target genes. Protein expression analysis revealed that mutant NR1H3 
(LXRA) alters gene expression profiles, suggesting a disruption in 
transcriptional regulation as one of the mechanisms underlying MS 
pathogenesis. The study indicates that pharmacological activation of LXRA 
or its targets may lead to effective treatments for the highly debilitating 
and currently untreatable progressive phase of MS. 
Even in the early stages of MS when physical disability is minimal, 
cognitive impairment can result in a lower health-related quality of life 
(e.g. greater fatigue, poorer physical well-being), a negative impact upon 
day-to-day activities and a reduced ability to work. 
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With the application of neuropsychological tests, evidence is 
accumulating that cognitive dysfunction is more prevalent and can occur 
in the course of the disease than had been estimated previously. 
The earlier MS can be diagnosed, the earlier treatment can be started - 
before further deterioration in brain health, relapses or irreversible 
disability occur. 
The total annual direct (medical and non-medical) and indirect costs of 
MS in Europe has been estimated at 15 euro billion; an average of 36000 
euro per person with MS. This is a greater annual cost per person than for 
other long-term conditions such as asthma, Alzheimer’s disease and 
diabetes. 
1.2 Different stages in multiple sclerosis 
Several clinical courses are usually distinguished in MS (Jekyll Island 
Meeting of MS Society 1995, reported in Lublin FD, 1996) in particular, a 
first neurological episode of clinical symptoms at the expense of CNS, 
lasting at least 24 hours, is known as a Clinically Isolated Syndrome (CIS). 
The CIS stage is caused by inflammation/demyelination in one (mono-
focal) or more (multi-focal) sites in the central nervous system and it could 
represent the first step for a subsequent confirmation of MS diagnosis. In 
fact not all patients who had a CIS not necessarily go on to develop the 
MS and this is depending on the similitude of lesions detected with those 
usually seen in the MS. Sometimes the myelin damage is spotted before 
any symptoms appear, via a brain scan conducted for another purpose 
(e.g. headaches). This is MS stage is called Radiologically Isolated 
Symptoms (RIS); people with RIS are at risk of developing CIS or MS. 
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To subsequently confirm diagnosis of the MS a series of criterion, defined 
as McDonald criteria, were developed in 2001 (McDonald WI, 2001) and 
lately updated in 2010 (Polman CH, 2011). They are based on number of 
lesions and attacks (relapses) observed in patients (Chapter 2.3).  
Once the MS is clinically confirmed the evolution of disease during time is 
highly variable from one patient to another one and basically it is possible 
to identify four different form of clinical course. 
Among all patients about 85% of them start with a Relapsing-Remitting 
(RRMS) form in which clearly defined periods, lasting from few days to 
weeks, of neurological symptoms, called relapse. 
Usually, a relapse develops over a few days, before the symptoms plateau 
and ease off (remit) over the next few weeks or months. Although 
patients can sometimes be complete recovery from a relapse (particularly 
early in the disease course), relapses are often associated with a 
measurable and sustained increase in disability. In the long term, 
incomplete recovery from relapses may contribute to the stepwise 
progression of disability. Early on in RRMS, nerve fibres are destroyed and 
the brain begins to atrophy. When this damage exceeds a certain 
threshold, the patient stage of progressive disability starts to be called 
Secondary Progressive MS (SPMS).  
In SPMS, disability gets continuously worse (with or without relapses) 
especially the ability to walk. It takes around 10-20 years for a person with 
RRMS to develop SPMS on average, and within 20-25 years up to 90% of 
them will have SPMS. Relapses lead to more pain, restricted mobility, an 
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increased risk of depressive symptoms, reduced functional ability and a 
lower health-related quality of life compared with a state of remission. 
Clinical and MRI data suggest that inflammation and the formation of new 
white matter lesions are the substrate for RRMS, while in the progressive 
phase new inflammatory demyelinating lesions are rare but diffuse 
atrophy of the grey and white matter and changes in the so-called normal-
appearing white matter become prominent. It has been suggested that in 
the early phase of the disease inflammation is the driving force, whereas 
the progressive phase may be underlined by a neurodegenerative 
process, which develops at least in part independent from inflammation. 
Around 10% of people with MS have a progressive disease course from 
the start, with no relapses and progressively worsening. This is known as 
Primary Progressive MS (PPMS) state. These patients are more likely to be 
older and male when compared with patients who have relapsing-
remitting disease. 
A small number of people are classified as having Benign MS (BMS), on 
the basis of their lack of or slow accumulation of clinically disability. 
However, this term can be misleading because it does not account for 
other aspects of the disease and a large proportion of people with MS 
classified as having BMS end-up becoming disabled. Patient with BMS 
have better physical disability outcome at 5 years compared to non-BMS 
cases. However, cognitive impairment frequency and decline over time 
appeared similar compared to other types of MS.  
Studies furthermore confirm that cognitive impairment was more 
accentuated in the BMS patients compared to the RRMS ones, assessed 
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with a response time test and a percentage of correct responses test. This 
suggest a silent deterioration of cognitive skills for the BMS that is not 
usually treated with pharmacological or neuropsychological therapy. 
Different stages of the disease suggests that the mechanisms of tissue 
injury are heterogeneous between patients and stage dependent within 
the same patient. 
The relapses and disease progression of the MS limit everyday activities, 
restrict participation in society and reduce health-related quality of life at 
all disease stages. 
Despite the devastating impact of the disease, people with the MS have 
their life expectancy reduced by only 5-10 years. This indicates that most 
of the MS people live with substantial disability for long time. 
1.3 Monitoring disease activity and progression in 
multiple sclerosis 
Currently, there are no symptoms, physical findings or laboratory 
assessments, which can help to identify the MS disease. No single test is 
proof-positive for diagnosing multiple sclerosis. Several strategies are 
used to determine if a person meets the long-established criteria for a MS 
diagnosis, and to rule out other possible causes. These strategies include 
a careful medical history, a neurologic exam and various tests including 
magnetic resonance imaging (MRI), evoked potentials (EP) and spinal fluid 
analysis. The EP test evaluates the electrical activity of the brain in 
response to a stimulation of a specific sensory nerve pathway. It is able to 
detect the slowing of the electrical conduction due to demyelination. 
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Spinal fluid test analyses a clear, colourless liquid that bathes the brain 
and spinal cord, cushioning the brain within the skull and serving as a 
shock absorber for the CNS. 
1.3.1 Relapses 
To monitor the clinical progression and the disease activity several 
measures of clinical evaluations are available for each MS stage. The 
clinical relapses represent the most reliable marker of disease activity. A 
relapse is defined as an episode of objective neurological dysfunction 
lasting a minimum of 24 hours and occurring more than 28 days from any 
previous neurological symptoms (Poser CM, 1983). 
Several drugs have been approved for the treatment of RR-MS on the 
basis of the reduction of the total number of relapses occurred over a 
fixed period of time  (Group, 1993; Johnson KP, 1995; Jacobs LD, 1996;  
PRISM, 1998; Polman CH O. P., 2006; Kappos L, 2010;). This quantity is 
known as relapse-rate and it is generally expressed as Annualized Relapse-
Rate (ARR). The ARR frequently represents the primary outcome in the 
phase III clinical trials, designed to assess the new drugs efficacy. 
Moreover recent works (Sormani MP, 2011; Wang YC, 2011) showed that 
the effects of the two most used drugs, Interferon (IFN) beta-1A and 
Natalizumab, on the progression of MS-related disability are largely 
mediated by the effects seen on relapses. 
In clinical trials involving CIS patients the standard primary endpoint is 
generally represented, instead, by the time at which the first relapse 
occur for each patients. This primary outcome can be expressed as Time 
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To First Relapse (TTFR) and will be investigated together with the ARR in 
this thesis. 
1.3.2 The Expanded Disability Status Scale (EDSS) 
Supervising the disability level of MS patients is frequently used as 
primary outcome in Phase III trials. Disability or disability changes during 
time are generally monitored using a standard tool represented by the 
Expanded Disability Status Scale (EDSS) (Kurtzke JF, 1983).  
The EDSS is a scale which ranges from 0 to 10 with increments of 0.5 with 
higher scores corresponding to a greater level of disability of the patient. 
Particularly EDSS steps 1.0 to 4.5 refer to people with MS who are fully 
ambulatory while steps 5.0 to 9.5 are defined by the impairment to 
ambulation. 
Administration time will vary depending upon the condition of the patient 
and the skill of the examiner. Although the EDSS themselves can be rated 
in a few minutes, the neurological examination that is needed to make 
the ratings can take anywhere from 15 minutes to a half-hour. The EDSS 
are administered in person by a trained examiner, most often a 
neurologist. However, nurse practitioners with the proper training can 
also complete the neurological examination and rate the EDSS.  
Even if the EDSS is largely used as outcome in clinical trials it has some 
limits. Firstly, is that it is heavily dependent on locomotors functions while 
appear to be less sensitive to neurological and cognitive dysfunction. 
Secondly, the EDSS Scores on the lower end of the scale are more 
dependent upon nuances in the neurological examination; those in the 
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middle range are more dependent upon gait, while those in the upper 
(more impaired) range are also dependent upon activities of daily living. 
Third, the EDSS is defined in a non-continuous scale but takes on ordinal 
values with steps of 0.5 and, as consequence, it has been observed that it 
is more susceptible to jumps along the scale rather than seeing a smooth 
decline or improvement. Moreover for its ordinal characteristic the 
difference between one step and the following has different meanings at 
different EDSS levels. 
Despite of same limits, the EDSS scale represents a familiar and widely 
used albeit imperfect standard, it will probably remain an important part 
of clinical assessment in the MS for the foreseeable future. 
1.4 Evidence for a two-stage disability progression in 
multiple sclerosis 
The MS is one of the most common causes of neurological disability in 
young adults. It is well established that axonal injury is a feature of 
multiple sclerosis (Charcot JM, 1880), that the extent of axonal injury is 
correlated with the degree of inflammation  (Trapp BD, 1998) at least in 
relapsing multiple sclerosis, and that a close association between 
inflammation and neurodegeneration might exist in all disease stages of 
multiple sclerosis (Kutzelnigg A, 2005;  Frischer J, 2009). However, the 
interdependence between focal inflammation, diffuse inflammation and 
neurodegeneration, and their relative contribution to clinical deficits 
remain ambiguous. Nevertheless, this point is central for understanding 
the mechanism of tissue injury in multiple sclerosis, which may have an 
effect on treatment.  
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Four large cohort studies have explored factors affecting the disability 
accrual at various stages of the MS and variables associated with early 
disease progression have been identified (Confavreux C, 2006).   
It has therefore been suggested that disability accrual at later MS stages 
is primarily driven by neurodegeneration and is largely independent of 
inflammation. These observations have led to a two-stage hypothesis, 
with the first stage representing a therapeutic window for modifying 
disease trajectory, which then becomes uniform in the second stage of 
disease (Leray E, 2010). This concept was also confirmed in others studies 
(Scalfari A, 2010; Stys PK, 2012). 
More recently, the variability and predictability of disability trajectories in 
the MS were evaluated in a large longitudinal data concluding that, the 
disability trajectories in moderately advanced MS are highly variable and 
the disability accumulation in moderately advanced and advanced MS 
remains substantially driven by inflammatory activity (Lizak N, 2017). 
1.5 Aim of the research 
In this context, the first aim of this research was to test the Leray 
hypothesis of MS as a two stage disease, by studying s disability 
trajectories over the disease course in MS patients using advanced 
statistical modelling approaches. 
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2 Materials and methods 
2.1 Patients and data collection 
Patients were identified through the MS Centre of Montichiari (Brescia, 
Italy) which is a territory-based centre created in 1980 mainly for patients 
of Brescia and province. All clinical evaluations of MS patients visited in 
the centre have been performed by four EDSS-certified neurologists 
(Capra R, 2017). All the MS outpatients included in the analysis were 
evaluated at our MS Centre between 1980 and 2016, diagnosed with MS 
according to the MS diagnostic criteria evolving over time (Inusah S, 2010; 
Kister I, 2012; Veugelers PJ, 2009) with a relapsing-remitting (RR) course 
at diagnosis and with age at diagnosis 18-60 years. The first symptom was 
considered MS onset if objectivized by a specialist and six different period 
of diagnosis were considered (1980-1990, 1991-1995, 1996-2000, 2001-
2005, 2006-2010, 2011+) as described in Capra et al. (Capra R, 2017). 
2.2 Disability milestone and inclusion criteria 
Disability was graded using the Kurtzke Expanded Disability Status Scale 
(EDSS) (Kurtzke JF, 1983). For the data analysis on disability accumulation, 
we took in to account two different neurological disability epochs. The 
first epoch, ranged between the first EDSS visit at diagnosis and EDSS 3 
(moderate disability but unrestricted ambulation), instead the second 
epoch come from EDSS 3 to the last EDSS visit (advanced disability). For 
each epoch (pre- and post-EDSS 3), the population of patients with 
clinically definite relapse-diagnosis MS were selected. Moreover, patients 
must have had an EDSS <3 at the first visit and they must have reached 
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the step of EDSS 3, confirmed over ≥6 months. Patients had ≥12 months 
of prospective follow-up prior to EDSS 3 and at least two visits post- EDSS 
3. A minimum required data set consisted of year of birth, gender, 
familiarity, date of the first clinical presentation and diagnosis of MS, 
disease course at diagnosis, age at on-set and EDSS at diagnosis. The post-
EDSS 3 epoch was selected to emulate the natural history studies 
(Confavreux C, 2006;  Lizak N, 2017).    
2.3 The Mixed-Effect Model 
2.3.1 Introduction 
The normal linear model (Fox, 2002), 
 =  +  +⋯+ 

 +  
~	0,  
has one random effect, the error term . The parameters of the model 
are the regression coefficients,  +  +⋯+ 
 and the error variance, 
. Usually,  = 1, and so  is a constant or intercept.  
For comparison with the linear mixed model of the next section, I rewrite 
the linear model in matrix form, 
 =  +  
~	0,  
where  = , , … , 
′ is the response vector;  is the model matrix, 
with typical row   = , , … , 
;  =  +  +⋯+ 
′  is the 
vector of regression coefficients;  =  +  +⋯+ 	is the vector of 
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errors; 	represents the n-variable multivariate-normal distribution; 0 is 
an  × 1 vector of zeroes; and  is the order n identity matrix. 
So-called mixed-effect models (or just mixed models) include additional 
random-effect terms, and are often appropriate for representing 
clustered, and therefore dependent, data – arising, for example, when 
data are collected hierarchically, when observations are taken on related 
individuals (such as siblings), or when data are gathered over time on the 
same individuals. 
There are several facilities in R and S-PLUS for fitting mixed models to 
data, the most ambitious of which is the nlme library (an acronym for non-
linear mixed effects), described in detail by Pinheiro (Pinheiro, 2000). 
Despite its name, this library includes facilities for fitting linear mixed 
models (along with nonlinear mixed models), the subject of the present 
appendix. There are plans to incorporate generalized linear mixed models 
(for example, for logistic and Poisson regression) in the nlme library. In the 
interim, the reader may wish to consult the documentation for the 
glmmPQL function in Venables and Ripley’s (Venables, 1999) MASS 
library1. 
Mixed models are a large and complex subject, and I will only scrape the 
surface here. I recommend Raudenbush and Bryk (Raudenbush, 2002) as 
a general, relatively gentle, introduction to the subject for social 
scientists, and Pinheiro and Bates (Pinheiro, 2000), which I have already 
mentioned, as the definitive reference for the nlme library. 
                                                          
1 Version 6.3-2 of the MASS library (or, I assume, a newer version) is required. 
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2.3.2 The linear Mixed-Effect Model 
The linear mixed model (Laird N, 1982; Verbeke G, 2000; Hedeker D, 
2006; Fitzmaurice G, 2009) has become a standard statistical method to 
analyse change over time of a longitudinal Gaussian outcome and assess 
the effect of covariates on it. 
Linear mixed models may be expressed in different but equivalent forms. 
In the social and behavioural sciences, it is common to express such 
models in hierarchical form. The lme (linear mixed effects) function in the 
nlme library, however, employs the Laird-Ware form of the linear mixed 
model (after a seminal paper on the topic published by Laird N, 1982): 
 =  +  +⋯+ 

 +	!" +⋯+ !#"# +  
!$~	0, %$, &'(!$ , !$ = )$$ 
 ~	0, *$, &'( ,   = 	*   
Where 
•  	is the value of the response variable for the j-th of 	 
observations in the ith of M groups or clusters. 
• , … , 
  are the fixed-effect coefficients, which are identical for all 
groups. 
•  , … , 
  are the fixed-effect repressors for observation j in 
group i; the first regressor is usually for the constant,	 = 1. 
• !, … , !# are the random-effect coefficients for group i, assumed 
to be multivariate normally distributed. The random effects, 
therefore, vary by group. The !$	are thought of as random 
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variables, not as parameters, and are similar in this respect to the 
errors  . 
• " , … , "# 	are the random-effect regressors. 
• %$ are the variances and )$$	the covariances among the random 
effects, assumed to be constant across groups. In some 
applications, the )’s are parametrized in terms of a relatively small 
number of fundamental parameters. 
•   is the error for observation j in group i. The errors for group i are 
assumed to be multivariately normally distributed. 
• 	*   are the covariances between errors in group i. Generally, 
the *  	are parameterised in terms of a few basic parameters, and 
their specific form depends upon context. For example, when 
observations are sampled independently within groups and are 
assumed to have constant error variance, *  = , *  + =
0		,'-	. ≠ .′, and thus the only free parameter to estimate is the 
common error variance,	. Similarly, if the observations in a 
“group” represent longitudinal data on a single individual, then the 
structure of the *’s may be specified to capture autocorrelation 
among the errors, as is common in observations collected over 
time. 
Alternatively but equivalently, in matrix form, 
 =  + 0! +  
!~	0,Ψ 
 33 
~	20, Λ 
where: 
• 	 is the  × 1 response vector for observations in the i-th group. 
• 	 is the  × 4 model matrix for the fixed effects for observations 
in group 5. 
• β	 is the 4 × 1 vector of fixed-effect coefficients. 
• 0	 is the  × 7 model matrix for the random effects for 
observations in group 5. 
• b	 is the 4 × 1 vector of random-effect coefficients for group 5. 
• 	 is the  × 1 vector of errors for observations in group 5. 
• Ψ	 is the7 × 4 covariance matrix for the random effects. 
• Λ	is the  ×  covariance matrix for the errors in group 5. 
Another way to define linear mixed model was proposed by Proust-Lima 
(Proust-Lima C, 2015). For each subject 5	in a sample of N subjects, let 
consider a vector of  repeated measures 9 = 9, … , 9 , … 92
:
 
where 9   is the outcome value at occasion j that is measured at time ; . 
We distinguish the time of measurement ;  from the occasion .	because 
an asset of the linear mixed model is that the times and the number of 
measurements can vary from a subject to the other. This makes it possible 
for example to include subjects with intermittent missing data and/or 
dropout, or to consider the actual individual time of measurement rather 
than the planned visit, which in some application can greatly differ.  
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Following Laird and Ware (Laird N, 1982), we define the linear mixed 
model as follows: 
9 = <; : + 0; := +>;  +    (1) 
where <	; and 0	;  are two vectors of covariates at time ;  of 
respective length 4	and 7. The vector <	;  is associated with the 
vector of fixed effects 	and 0	; , which includes typically functions of 
time	; , is associated with the vector of random-effects =. Shapes of 
trajectories considered in <	and 0	 can be of any type (polynomial 
(Proust C, 2005), specifically designed to fit the trajectory (Proust-Lima C 
A. H.-G., 2013), or approximated using a basis of splines). 
The vector =  of 7	random-effects has a zero-mean multivariate normal 
distribution with variance-covariance matrix B, where B is an unspecified 
matrix. The measurement errors 	are independent Gaussian errors with 
variance ?. Finally, the process >; @∈ℝ is a zeromean Gaussian 
stochastic process (e.g., Brownian motion with covariance 
C'(	>;, >D = E min 	;, D or a stationary process with 
covariance C'(	>;, >D = E I4−4|; − D|. 
The vector of parameters to estimate is : , (IC: , E , L, ?: where 
(IC		 is the vector of parameters involved for modelling the symmetric 
positive definite matrix M. 
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2.4 The Latent class growth analysis 
2.4.1 Overview 
Researchers in the fields of medical, social and psychological sciences are 
often interested in modelling the longitudinal developmental trajectories 
of individuals, whether for the study of personality development or for 
better understanding how clinical characteristics unfold over time 
(whether it be days, months, or years). This usually requires an extensive 
dataset consisting of longitudinal, repeated measures of variables, 
sometimes including multiple cohorts, and analysing this data using 
various longitudinal latent variable modelling techniques such as latent 
growth curve models (MacCallum, 2000). The objective of these 
approaches is to capture information about inter-individual differences in 
intra-individual change over time (Nesselroade, 1991). 
However, conventional growth modelling approaches assume that 
individuals come from a single population and that a single growth 
trajectory can adequately approximate an entire population. Also, it is 
assumed that covariates that affect the growth factors influence each 
individual in the same way. Yet, theoretical frameworks and existing 
studies often categorize individuals into distinct subpopulations (e.g., 
socioeconomic classes, age groups, at-risk populations). For example, in 
the field of alcohol research, theoretical literature suggests different 
classes of alcohol use initiation patterns, e.g., ‘early’ versus ‘late’ onsetters 
(Hill, 2000). Using Growth Mixture Modelling (GMM) with five different 
indices of alcohol use (alcohol use disorder, alcohol dependence, alcohol 
consequences, past year alcohol quantity and frequency, and heavy 
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drinking), Jackson and Sher (Jackson, 2005) identified four distinct classes 
for each measure. The results of these studies confirm theoretical 
contentions that heterogeneity of growth trajectories exist within the 
larger population. In addition, these findings suggest that describing an 
entire population using a single growth trajectory estimate is 
oversimplifying the complex growth patterns that describe continuity and 
change among members of different groups. Instead, a latent class or 
growth mixture modelling approach seems to be the most appropriate 
method for fully capturing information about inter-individual differences 
in intra-individual change taking into account unobserved heterogeneity 
(different groups) within a larger population (Jung T, 2008). 
A useful framework for beginning to understand latent class analysis and 
growth mixture modelling is the distinction between person-centred and 
variable-centred approaches (Muthén, 2000). Variable-centred 
approaches such as regression, factor analysis, and structural equation 
modelling focus on describing the relationships among variables. The goal 
is to identify significant predictors of outcomes, and describe how 
dependent and independent variables are related. Person-centred 
approaches, on the other hand, include methods such as cluster analysis, 
latent class analysis, and finite mixture modelling. The focus is on the 
relationships among individuals, and the goal is to classify individuals into 
distinct groups or categories based on individual response patterns so 
that individuals within a group are more similar than individuals between 
groups. 
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2.4.2 The Latent Process Mixed Model 
The linear mixed model applies to longitudinal markers that are 
continuous, have Gaussian random deviations (random-effects, 
correlated errors and measurement errors) and it assumes that the 
covariate effects are constant (β) along the entire range of the marker 
values. In practice, these assumptions do not hold for many longitudinal 
outcomes, especially psychological scales. The generalized linear mixed 
model extends the theory to binary, ordinal or Poisson longitudinal 
outcomes (Hedeker D, Longitudinal data analysis., 2006); (Fitzmaurice G, 
Longitudinal data analysis, 2009). In order to study non Gaussian 
longitudinal markers, we chose another direction by defining a family of 
mixed models called the latent process mixed models (Proust C J.-G. H., 
2006); (Proust-Lima C A. H.-G., Analysis of multivariate mixed longitudinal 
data: A flexible latent process approach, 2013). Coming from the latent 
variable framework, this approach consists in separating the structural 
model that describes the quantity of interest (a latent process) according 
to time and covariates from the measurement model that links the 
quantity of interest to the observations. 
The latent process Λ; is defined in continuous time according to a 
standard linear mixed model without error of measurement: 
Λ; = <;: + 0;:= + >;,				∀	; ∈ ℝ  (2) 
where <;, 0; and 	>; are defined in section 3.3.2. 
In order to take into account different types of longitudinal markers, a 
flexible nonlinear measurement model is defined between the latent 
 38 
process and		>;  and the observed value 9  at the measurement time 
; . 
9 = Q9RST;V	 = QΛ;  +  ; V   (3) 
where   are independent Gaussian measurement errors with variance 
W, H is a parameterized link function and 9  denotes the noisy latent 
process at time ; . 
For a quantitative marker, QX is a monotonic increasing continuous 
function. Are currently implemented: 
• the linear transformation that reduces to the Gaussian framework 
of the linear mixed model: 
QX9  =
9 − V
V  
• the rescaled cumulative distribution function (CDF) of a Beta 
distribution: QX9 ; 	V =
YZ[2\∗ ;^_;	^`aX^b
^c   with ℎ9 
∗ ; V; 	V =
e fg_
∗h_Xfg∗`h_
i^_∗ ,^∗`
	j,[2\∗k 	MV∗, V∗ is the complete 
Beta function. For positiveness properties of canonical parameters 
V∗ and V∗  and computation reasons, the Beta distribution is 
parameterized as follows: V∗ = l
g_
lg`Xlg_  and  V∗ =

lg_mlg` . In 
addition, 9  is rescaled in (0, 1) using 9 =	 [2\X	nop[	m	Wq	nrs[Xnop[mWq with 
the constant t[ > 0	 and	min9	 and 	max	9	 the (theoretical or 
observed) minimum and maximum values of 9. 
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• a basis of quadratic I-splines with m knots: QX9 ; 	V = Vk +
	∑ VxMxy9 zmx{  with Mxy, … , Mzmy  the basis of I-splines (Ramsay, 
1988). 
For an ordinal or binary marker (with M levels), equation (3) reduces to a 
probit (cumulative) model with 9 = QΛ;  + t ; 	V = |k + } if 
Λ;  + t ∈ 	 ~Vx∗, Vxm∗ 	for } = 0, …	,| − 1,|k	the minimum value of 
the marker, Vk =	Vx∗ =	−∞, V = V∗ =	+∞  and   V∗ =	V, Vx∗ = V +
	∑ V x { 	for	} < 1 to ensure increasing thresholds  Vk∗ < V∗, …	 , VX∗ <
V∗ 	 for the noisy latent process. 
Latent process mixed models need two constraints to be identified: one 
on the location of the latent process managed by the intercept effect 
k = 0 and one for the scale of the latent process managed by W = 1. 
So the vector of parameters to estimate is :, (ICM: , E, L, V:: 
where	(ICM is defined in section 3.3.2. 
2.4.3 The Latent Class Linear Mixed Model 
The linear mixed model assumes that the population of N subjects is 
homogeneous and described at the population level by a unique profile 
<;:. In contrast, the latent class mixed model consists in assuming 
that the population is heterogeneous and constituted of G latent classes 
of subjects characterized by G mean profiles of trajectories. Each subject 
belongs to one and only one latent class so that the latent class 
membership is defined by a discrete random variable ci that equals  if 
subject 5 belongs to latent class g	g	 = 	1, . . . , G. The variable ci is latent; 
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its probability is described using a multinomial logistic model according to 
covariates : 
 = C = | = l
2 _
∑ l2 __
  (6) 
where x is the intercept for class 	 and  is the q1-vector of class-
specific parameters associated with the q1-vector of time-independent 
covariates . For identifiability, the scalar   and the vector = 0. 
When no covariate predicts the latent class membership, this model 
reduces to a class-specific probability. 
The G mean profiles are defined according to time and covariates through 
latent class specific mixed models. The difference with a standard linear 
mixed model is that both fixed effects and the distribution of the random-
effects can be class-specific. For a Gaussian outcome, the linear mixed 
model defined in (1) becomes for class g: 
9 |2{ = <; 
: + <; : + 0; := +>;  +   
 (7) 
where <;  previously defined is spitted in <;  with common 
fixed effects β over classes and <;  with class-specific fixed effects 
. The vector 0;  is still associated with the individual random-effects 
=|2{ called = in equation (7) whose distributions is now class-specific. 
In class g, they have a zero-mean multivariate normal distribution with 
variance-covariance matrix >M, where M is an unspecified variance 
covariance matrix and >  is a proportional coefficient (> = 1 for 
identifiability) allowing for a class-specific intensity of individual 
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variability. The auto-correlated process >; and the errors of 
measurement   are the same as in section 3.3.2. 
This extension of the linear mixed model also applies to the latent process 
mixed model described in sections 3.3.2 by replacing the structural model 
in (2) by:  
9 |2{ = <; 
: + <; : + 0;:= +>;  
 (8) 
The location constraint for this model becomes k = 	0 that is the mean 
intercept in the last class is constrained to 0. The scale constraint remains 
unchanged. The measurement models remain the same by assuming the 
heterogeneity in the population only affects the underlying latent process 
of interest. The vector of parameters to estimate defined in sections 2.1, 
2.2 and 2.3 include now also Z, : {,X, 	:{,X, >{,Xa 
2.4.4 Post-fit computations 
In the following, the symbol hat (ˆ) denotes the value of a 
parameter/vector/matrix/function computed at the maximum likelihood 
estimates . 
2.4.4.1 Maximum Likelihood Estimates 
This subsection applies to the four estimation functions. The table of the 
maximum likelihood estimates along with their estimated standard error 
are given in function summary. The vector is directly given by function 
estimates or in output value best. The estimated variance-covariance 
matrix of the maximum likelihood estimates is given in function VarCov 
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and in output value V. In the latter, the upper triangular matrix is given as 
a vector. 
The parameters of the variance-covariance matrix of the random-effects 
are not directly estimated although they are provided in the summaries. 
The Cholesky parameters used for the estimation are available in output 
vector cholesky or in function estimates. Estimated standard-errors of the 
parameters of the variance-covariance matrix are computed in function 
VarCovRE in the lccm package (Proust-Lima C, 2015). 
2.4.4.2 Posterior classification 
In models involving latent classes, a posterior classification of the subjects 
in each latent class can be done. It is based on the posterior calculation of 
the class-membership probabilities. It is used to characterize the 
classification of the subjects as well as to evaluate the goodness of fit of 
the model (Proust-Lima C, 2015). 
- Class-membership posterior probabilities and classification 
The posterior class-membership probabilities are computed using 
the Bayes theorem as the probability of belonging to a latent class 
given the information collected. In a longitudinal model, they are 
defined for subject 5 and latent class  as 
[ = & = |<,  ,  	 =
 9|& = , 
∑ xx{  x9|& = }, 
 
In a joint latent class model, the complete information also includes 
the time-to-event so that for subject 5 and latent class , the 
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posterior class-membership probability can also be defined for 
subject 5 and latent class  as 
[,: = & = |<,  , ¡, 9 , ¢ , £ ,  	 = 
 9|& = , I∑ :2|2{,¤¥¦§_ ∏ *¢|C = , ©2§ª
{
∑ xx{  x9|& = }, I∑ «§:2|2{x,¤¥
¦§_ ∏ *
¢|C = }, ©2§ª
{
 
A posterior classification can be obtained from these posterior 
probabilities by assigning for each subject the latent class in which 
he has the highest posterior class-membership probability Ĉ 	=
	­-®­[	'-	Ĉ 	= 	­­-®­[,:. 
 
- Posterior classification 
The posterior classification can be used to assess the goodness-of-
fit of the model (for the selection of the number of latent classes 
for instance) and the discrimination of the latent classes. Many 
indicators can be derived from it (Proust-Lima C, 2015). The package 
lcmm provides two indicators in the function postprob: 
o the proportion of subjects classified in each latent class with 
a posterior probability above 0.7, 0.8 and 0.9. This indicates 
the proportion of subjects not ambiguously classified in each 
latent class. 
o the posterior classification table as defined in table 2 which 
computes the mean of the posterior probabilities to belong 
to the latent class among the subjects classified a posteriori 
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in each latent class. A perfect classification would provide 
ones in the diagonal and zeros elsewhere. In practice, high 
diagonal terms indicate a good discrimination of the 
population. 
Table 1: Posterior classification table provided in function 
postprob 
Final 
class 
&¯ 
# 
Mean of the probability of belonging to each 
class 
1 …  … ° 
1 
1
± ²
.³_
{
 … 1± ²
.³_
{
 … 1± ²
.³_
{
 
…  ⋮ ⋱    
 
1
± ²
.³
{
 … 1± ²
.³
{
 … 1± ²
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2.5  Statistical analysis 
Continuous variables are given as means and standard deviations (SD), 
whereas categorical variables as number and/or percentage of subjects. 
The outcome of interest were the disability EDSS trajectory slopes in the 
spam of time prior to and following the EDSS 3 status, that were 
calculated with a Mixed-Effect Model (MEM) over the pre- or the post- 
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EDSS 3 scores (including the EDSS 3 score in both). The disease 
progression slope and variability were respectively examined using t test 
and F Variance test through the individual EDSS slopes for the pre- and 
post-EDSS 3 periods.  
In order to investigate different longitudinal disability trajectories during 
pre- and post-EDSS 3 epoch, a Latent Class Mixed-effect Model (LCMM) 
was performed using the fitted EDSS values of the MEM as the dependent 
variable and the disease duration from MS diagnosis was entered as 
covariate in the model. A linear disease duration term was used to specify 
for the random-effects in the latent process mixed model, i.e., the 
individual variation around the mean trajectory (of the individual's latent 
class). Models with one, two, three, etc., latent trajectory classes were fit 
and to select the best model in term of the number of classes detected, 
the parsimony seeks minimum values for information criteria (Akaike 
Information Criterion and, Bayesian Information Criterion) was adopted. 
Correlation among classification pre- and post-EDSS 3 epoch was 
performed using chi-square or Fisher's Exact Test.  
The disability trajectories over the disease course were studied, using 
again, the LCMM including disease duration as covariates with the EDSS 
disability score as the outcome measure. The linear disease duration were 
used to specify for the random-effects in the LCMM. After choosing the 
best model as describe above, univariate analysis was performed using 
logistic regression, to screen possible determinants of class membership 
among clinical and demographic characteristics, such as gender, 
familiarity, group of diagnosis, age at diagnosis, therapy delay, median 
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among EDSS visits, age at on-set and EDSS at diagnosis. Those covariates 
with a p-value <0.05 were then selected for the multivariate analysis, 
where the logistic regression model was again used. Differences, with a 
p-value less than 0.05, were selected as significant and data were 
acquired and analysed in R v3.4.3 software environment (R, 2017). 
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3 Results 
A total of 227 (153 male and 74 female) out of 1442 MS relapsing-
remitting patents diagnosed between 1980 and 2016 fulfilled the 
inclusion criteria for each epoch (pre- and post-EDSS 3). As regard 
selection criteria, 1077 patients had an EDSS < 3 at the first visit, 329 
patients reached EDSS 3, a pre-EDSS 3 prospective follow-up ≥12 months 
was observed in 253 patients and 239 patients had at least two visits post-
EDSS 3. The excluded patients majority had not had reached the EDSS 3 
status yet (N=662) following by patients that had an EDSS great than 3 at 
the first visit (N=247). 
The demographic and clinical characteristics of the study participants are 
summarised in Table 1. Briefly for 621 patients that no reached EDSS 3, 
207 were male while 455 were female. The mean of EDSS at diagnosis was 
1.22 (SD=0.97) instead, the age at onset and diagnosis means were 30.95 
(SD=8.79) and 33.5 (SD=9.18) years, respectively. Seventy-four (32.6%) 
patients had a MS familiarity. As regard patients that reached EDSS 3, the 
mean age at diagnosis was 33.5 years (SD=9.18; range = 18.29 : 59.53 
years).  The means of age at onset was 31.43 (SD=9.59) and the mean of 
EDSS at diagnosis was 1.67 (SD=1.15). Twenty-five (11.01%) patients had 
a MS familiarity.  
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3.1 Classification of EDSS trajectory slopes versus 
disease duration 
To find a model that provides the best fit to the data for the pre- and post 
EDSS 3 epoch, five latent class models were performed increasing the 
number of classes from 1 until 5.  
As regard the per-EDSS 3 epoch, the Akaike Information Criterion (AIC) 
and, Bayesian Information Criterion (BIC) were reported in Figure 1 for 
different models taken into account. The lowest BIC and AIC was obtained 
for model with two latent trajectory classes (BIC= -23847.87; AIC= -
23912.94). When patients were assigned to the two classes, based on 
maximum posterior probabilities, there were 197 and 30 patients 
assigned to class 1 and 2 (Table 2; mean of posterior probabilities in each 
class: 94% and 80%, respectively). The plot of the disability EDSS 
trajectory slopes with two latent trajectory classes was reported in Figure 
2. In particular, moderate disability EDSS trajectory (magenta latent 
trajectory) and high disability EDSS trajectory (red latent trajectory) were 
identified. 
As regard distribution of the clinical and demographic characteristics in 
the two classes, similar gender, familiarity distribution, age at diagnosis 
and at onset means in two classes were observed (Table 3), instead the 
EDSS at diagnosis mean in moderate disability class was greater than that 
in high disability class (1.83 versus 0.63).  
Considering post-EDSS 3 epoch, the AIC and, BIC were reported in Figure 
3 for different models taken into account. The lowest BIC and AIC was 
obtained for model with two latent trajectory classes (AIC= 32337.04;  
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BIC= -32285.67). When patients were assigned to the two classes, based 
on maximum posterior probabilities, there were 159 and 68 patients 
assigned to class 1 and 2 (Table 4; mean of posterior probabilities in each 
class: 92% and 88%, respectively). The plot of the disability EDSS 
trajectory slopes with two latent trajectory classes was reported in Figure 
4. In particular, moderate disability EDSS trajectory (orange latent 
trajectory) and high disability EDSS trajectory (green latent trajectory) 
were identified. 
As regard distribution of the clinical and demographic characteristics in 
the two classes, similar gender, familiarity distribution, EDSS at diagnosis 
mean, age at diagnosis and at onset means in two classes were observed 
(Table 5). 
The plot of the disability EDSS trajectory slopes with the selected latent 
trajectory classes were reported in Figure 5 for pre- and post-EDSS 3 
epoch.  
The disability trajectory slope mean was 0.08 (SD= 0.04) for pre-EDSS 3 
epoch while, a mean of 0.11 (SD=0.23) disability trajectory slope was 
estimated for the post-EDSS 3 epoch (Table 6). The histogram of the 
disability trajectory slopes was reported in Figure 6, for the spam of time 
prior to (panel A) and following to (panel B) the EDSS 3 status. The 
graphical evaluation showed that the disability trajectory slopes were 
differently and highly variable, as significant evidenced by the F test to 
compare variances (variance ratio=0.02; p-value<0.0001). 
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The distribution among pre- and post- EDSS 3 latent trajectory classes  
was reported in table 7. The chi-square test, performed to assay whether 
observations on two variables were independent of each other, showed 
no significant association between the pre-EDSS 3 classes and the post-
EDSS 3 classes (p-value = 0.6647). 
3.2  Classification of EDSS score trajectories 
A total of 881 (602 female; 68.33%) disability EDSS score trajectories over 
the disease course of patents diagnosed between 1980 and 2016 were 
studied. The demographic and clinical characteristics of the study 
participants are summarised in Table 8. Briefly the mean of EDSS at 
diagnosis was 1.34 (SD=1.03) instead, the age at onset and diagnosis 
means were 31.08 (SD=9) and 33.71 (SD=9.21) years, respectively. 
Seventy-seven (32.6%) patients had a MS familiarity. The mean therapy 
delay was 38.31 months (SD=47.98).  
The disability trajectories over the disease course were studied by five 
Latent Class Mixed-effect Model (LCMM) increasing the number of classes 
from 1 until 5. The Akaike Information Criterion (AIC) and, Bayesian 
Information Criterion (BIC) were reported in Figure 7 for different models 
taken into account. The lowest BIC and AIC was obtained for model with 
three latent trajectory classes (AIC= 34984.11; BIC = 35098.86). When 
patients were assigned to the three classes, based on maximum posterior 
probabilities, there were 198, 633 and 50 patients assigned to class 1, 2 
and 3 (Table 9; mean of posterior probabilities in each class was 55% 61% 
and 77%, respectively). The plot of the disability EDSS trajectory scores 
with three latent trajectory classes was reported in Figure 8. In particular, 
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the trajectories of class 1 and 2 (magenta and blue dodger, respectively) 
had very similar graphic trend, so it was decided to aggregate this two 
similar trajectory in one that it was defined as moderate disability 
trajectory.  
The new two trajectory classes were reported in Figure 9 and moderate 
disability EDSS trajectory (blue latent trajectory) and high disability EDSS 
trajectory (forest green latent trajectory) were identified. 
As regard distribution of the clinical and demographic characteristics in 
the two classes, similar gender, familiarity distribution, period of 
diagnosis, median among EDSS visits, EDSS at diagnosis and therapy delay 
in two classes were observed (Table 10). Instead, the age at onset and at 
diagnosis means were greater in high disability class compared with those 
in moderate disability class, as significant evidenced by the univariate 
analysis (p-values: 0.0035 and 0.0023, respectively). The multivariate 
analysis (Table 11) highlighted the significant effect of age at diagnosis on 
high disability class membership (p-values=0.0023). In particular, a one-
unit increase in age at diagnosis was associated with a increased chances 
5% (OR=1.05) of having high disability class membership. 
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4 Conclusions 
The main aim of this research was to explore whether disability accrual in 
moderately and advanced MS is ascribable to the concept of multiple 
sclerosis as a two-stage disease as proposed by Leray at al. (Leray E, 2010). 
The second aim, but not less important, was to study disability trajectories 
over the disease course in MS patients. 
The research was conducted using patients identified through the MS 
Centre of Montichiari (Brescia, Italy) which is a territory-based centre 
created in 1980 mainly for patients of Brescia and province. After defining 
disability milestone and selecting patients (see section 3.2), the EDSS 
disability trajectory slopes were studied. The graphical and analytic 
evaluation among disability trajectory slopes in pre- and post-EDSS 3 
epoch showed that they were differently and highly variable (see section 
4.1). The Latent Class Growth Analysis identified two main disability 
trajectories in both pre- and post-EDSS 3 epoch. No significant 
association, between the main disability trajectories, was observed using 
chi-square test (p-value = 0.6647). In contrast to the study of Leray et al. 
(Leray E, 2010), we have shown that disability trajectories in advanced MS 
are highly variable as recently showed by Lizak (Lizak N, 2017). Moreover, 
our results concur that the disability trajectories in advanced disease 
(post-EDSS 3) is independent of previous disability trajectories (pre-EDSS 
3). 
Regarding disability trajectories over the disease course, the lowest BIC 
and AIC was obtained for model with three latent trajectory classes with 
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a mean of posterior probabilities in each class of 55% 61% and 77%, 
respectively. The first two probabilities evidence that the measured EDSS 
trajectories had poor membership in each latent class. the proportion of 
subjects could be ambiguously classified in this two latent class. Two 
trajectories out of 3 had very similar graphic trend, so it was decided to 
aggregate this two similar trajectory in one that it was defined as 
moderate disability trajectory. The next univariate and then multivariate 
analysis, performed to screen possible determinants of class membership 
among clinical and demographic characteristics, highlighted the 
significant effect of age at diagnosis on high disability class membership 
(p-values=0.0023). In particular, a one-unit increase in age at diagnosis 
was associated with an increased chances 5% (OR=1.05) of having high 
disability class membership. 
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5 Tables and Figures 
 
Table 1: The demographic and clinical characteristics of the study participants. 
The results are expressed as mean with standard deviation or as number of 
subjects with percentage 
Characteristic 
Patients 
No Reached 
EDSS 3 
(N=662) 
Patients 
reached 
EDSS 3 
(N=227) 
Gender   
Male 207 (31.27%) 153 (67.4%) 
Female 455 (68.73%) 74 (32.6%) 
Familiarity   
No 52 (7.85%) 202 (88.99%) 
Yes 610 (92.15%) 25 (11.01%) 
Diagnosis   
1980-1990 94 (14.2%) 27 (11.89%) 
1991-1995 28 (4.23%) 34 (14.98%) 
1996-2000 181 (27.34%) 58 (25.55%) 
2001-2005 17 (2.57%) 58 (25.55%) 
2006-2010 198 (29.91%) 44 (19.38%) 
2011+ 144 (21.75%) 6 (2.64%) 
Age at diagnosis 33.5 (9.18) 34.39 (9.5) 
Age at onset 30.95 (8.79) 31.43 (9.59) 
EDSS at diagnosis 1.22 (0.97) 1.67 (1.15) 
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Figure 1: Akaike Information Criterion (AIC) and, Bayesian Information 
Criterion (BIC) were reported for different models with different 
latent trajectory classes in the pre-EDSS 3 epoch. 
 
 
Table 2: Posterior classification table of the model with two different  
latent trajectory classes are reported for the pre-EDSS 3 epoch. 
 
Posterior classification:  
  class1 class2 
N 197.00  30.00 
%  86.78  13.22 
  
Posterior classification table:  
     --> mean of posterior probabilities in each 
class  
        prob1  prob2 
class1 0.9397 0.0603 
class2 0.1966 0.8034 
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Figure 2: Plot of the disability EDSS trajectory slopes with two latent 
trajectory classes are reported for the  pre-EDSS 3 epoch. 
 
Table 3: Contingency tables of the clinical and demographic  
distribution characteristics in the two latent classes 
Characteristic 
Classification of EDSS disability trajectories  
Pre-EDSS 3 
moderate  
(magenta) 
high  
(red) 
Gender   
Male 134 (87.58%) 19 (12.42%) 
Female 63 (85.14%) 11 (14.86%) 
Familiarity   
No 177 (87.62%) 25 (12.38%) 
Yes 20 (80%) 5 (20%) 
Diagnosis   
1980-1990 24 (88.89%) 3 (11.11%) 
1991-1995 30 (88.24%) 4 (11.76%) 
1996-2000 48 (82.76%) 10 (17.24%) 
2001-2005 50 (86.21%) 8 (13.79%) 
2006-2010 39 (88.64%) 5 (11.36%) 
2011+ 6 (100%) 0 (0%) 
Age at diagnosis 34.43 (9.6) 34.14 (9.02) 
Age at onset 31.28 (9.74) 32.42 (8.65) 
EDSS at diagnosis 1.83 (1.12) 0.63 (0.69) 
 57 
 
Figure 3: Akaike Information Criterion (AIC) and, Bayesian Information 
Criterion (BIC) were reported for different models with different 
latent trajectory classes in the post-EDSS 3 epoch. 
 
 
Table 4: Posterior classification table of the model with two different  
latent trajectory classes are reported for the pre-EDSS 3 epoch. 
 
Posterior classification:  
  class1 class2 
N 159.00  68.00 
%  70.04  29.96 
  
Posterior classification table:  
     --> mean of posterior probabilities in each 
class  
        prob1  prob2 
class1 0.9183 0.0817 
class2 0.1246 0.8754 
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Figure 4: Plot of the disability EDSS trajectory slopes with two latent 
trajectory classes are reported for the post-EDSS 3 epoch. 
 
Table 5: Contingency tables of the clinical and demographic  
distribution characteristics in the two classes 
Characteristic 
Classification of EDSS disability trajectories  
Post-EDSS 3 
moderate   
(green) 
high  
(red) 
Gender   
Male 108 (70.59%) 45 (29.41%) 
Female 51 (68.92%) 23 (31.08%) 
Familiarity   
No 142 (70.3%) 60 (29.7%) 
Yes 17 (68%) 8 (32%) 
Diagnosis   
1980-1990 17 (62.96%) 10 (37.04%) 
1991-1995 26 (76.47%) 8 (23.53%) 
1996-2000 39 (67.24%) 19 (32.76%) 
2001-2005 36 (62.07%) 22 (37.93%) 
2006-2010 35 (79.55%) 9 (20.45%) 
2011+ 6 (100%) 0 (0%) 
Age at diagnosis 33.81 (9.27) 35.75 (9.97) 
Age at onset 31.06 (9.42) 32.3 (9.98) 
EDSS at diagnosis 1.7 (1.22) 1.62 (0.98) 
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Figure 5: The plot of the disability EDSS trajectory slopes with the selected 
latent trajectory classes in the pre- and post-EDSS 3 epoch. 
 
 
Table 6: Descriptive statistics of the disability trajectory slope 
Statistics Pre-EDSS 3 Post-EDSS 3 
Min. 0.00 -0.57 
1st quantile 0.04 -0.03 
Median 0.08 0.08 
Mean 0.08 0.11 
3rd quantile 0.10 0.25 
Max. 0.23 0.93 
Standard deviation 0.04 0.23 
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Figure 6: the disability EDSS trajectory slope histograms in the spam of time 
prior to (panel A) and following (panel B) the EDSS 3 status. 
 
 
Table 7: Contingency table among pre- and post-EDSS 3 latent trajectory 
classes. The Count, Column Percent and Total Percent are reported in each 
cell. 
  Pre-EDSS 3  
Row Total 
Pre-EDSS 3  Moderate High 
Moderate  
   139 
87.42% 
61.23% 
    58 
85.29% 
25.55% 
      197 
86.78% 
High  
    20 
12.58% 
8.81% 
     10 
14.71% 
 4.41% 
    30 
13.22% 
Column Total 159 68 227 
  
Pearson's Chi-squared test        p-value =0. 6647 
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Table 8: The demographic and clinical characteristics 
 of the study participants (N=881). 
The results are expressed as mean with standard deviation  
or as number of subjects with percentage 
Characteristic Overall 
Gender  
Male 279 (31.67%) 
Female 602 (68.33%) 
Diagnosis  
1980-1990 44 (4.99%) 
1991-1995 62 (7.04%) 
1996-2000 152 (17.25%) 
2001-2005 201 (22.81%) 
2006-2010 239 (27.13%) 
2011+ 183 (20.77%) 
Familiarity  
No 804 (91.26%) 
Yes 77 (8.74%) 
Age at diagnosis (years) 33.71 (9.21) 
Age at onset (years) 31.08 (9) 
EDSS at diagnosis 1.34 (1.03) 
Median among EDSS visits (days) 180.43 (133) 
Therapy delay (Months) 38.31 (47.98) 
 
Figure 7: Akaike Information Criterion (AIC) and, Bayesian Information 
Criterion (BIC) were reported for different models with different 
latent trajectory classes (N=881). 
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Table 9: Posterior classification table of the model with three 
different latent trajectory classes are reported for all EDSS scores 
(N=881). 
 
Posterior classification:  
  class1 class2 class3 
N 198.00 633.00  50.00 
%  22.47  71.85   5.68 
  
Posterior classification table:  
     --> mean of posterior probabilities in 
each class  
        prob1  prob2  prob3 
class1 0.5530 0.4432 0.0037 
class2 0.3689 0.6089 0.0222 
class3 0.0604 0.1659 0.7737 
  
 
 
Figure 8: the disability EDSS trajectory scores with the three different latent 
trajectory classes are reported (N=881). 
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Figure 9: the disability EDSS trajectory scores with the two different latent 
trajectory classes are reported (N=881). 
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Table 10: Descriptive statistics with univariate analysis. 
Characteristic: variable taken into account;  
OR (95% CI): Odd Ratios with 95% Confidence Interval; p-value: Likelihood Ratio p-
value. 
 *Variables entering the multivariate analysis (see the text for abbreviations and 
further details). 
 Descriptive statistics Univariate analysis 
Characteristic 
moderate  
(blue) 
high  
(dark-green) 
OR (95% CI) p-value 
Gender    0.1139 
Male 258 (92.47%) 21 (7.53%) 1  
Female 573 (95.18%) 29 (4.82%) 
0.62 (0.35 : 
1.12) 
 
Diagnosis     0.3010 
1980-1990 41 (93.18%) 3 (6.82%) 1  
1991-1995 59 (95.16%) 3 (4.84%) 
0.69 (0.12 : 
3.92) 
 
1996-2000 143 (94.08%) 9 (5.92%) 
0.86 (0.24 : 
4.01) 
 
2001-2005 182 (90.55%) 19 (9.45%) 
1.43 (0.46 : 
6.27) 
 
2006-2010 226 (94.56%) 13 (5.44%) 
0.79 (0.24 : 
3.54) 
 
2011+ 180 (98.36%) 3 (1.64%) 
0.23 (0.04 : 
1.27) 
 
Familiarity    0.7501 
No 759 (94.4%) 45 (5.6%) 1  
Yes 72 (93.51%) 5 (6.49%) 
1.17 (0.4 : 
2.79) 
 
Age at diagnosis  
(yeas) * 
33.47 (9.12) 37.66 (9.86) 
1.05 (1.02 : 
1.08) 
0.0023 
Age at onset  
(yeas) * 
30.85 (8.9) 34.8 (9.91) 
1.05 (1.02 : 
1.08) 
0.0035 
EDSS at diagnosis 1.34 (1.04) 1.32 (0.98) 
0.98 (0.74 : 
1.29) 
0.8974 
Median among  
EDSS visits (days) 
178.47 (95.42) 213.17 (402.84) 
1.00 (0.99 : 
1.01) 
0.1743 
Therapy delay 
 (months) 
37.51 (48.27) 48.92 (42.98) 
1.00 (0.99 : 
1.01) 
0.1389 
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Table 11: Multivariate analysis, the predictor effects on the high disability 
class. Results are expressed as odds ratio (OR) with 95% confidence interval 
(95%CI). 
Characteristic OR (95% CI) p-value 
(Intercept) 0 0.01 (0 - 0.04) <0.0001 
Age at diagnosis (years) 1.05 (1.02 - 1.08) 0.0023 
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